Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells

European Journal of Pharmacology

Volumn 741, Issue , 2014, Pages 311-315

  Al Sabah, S ^a   Al Fulaij, M ^a   Ahmed, H A ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

G protein coupled receptor; GIP; GLP 1; Pro3GIP

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HORMONE RECEPTOR; INCRETIN; LIGAND; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DOSE RESPONSE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; INCRETINS; LIGANDS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON;

EID: 84907068044     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.08.019     Document Type: Article

References (30)

1. B. Ahren The future of incretin-based therapy: novel avenues - novel targets Diabetes Obes. Metab. 13 Suppl. 1 2011 S158 S166
2. M.A. Al-Fulaij, Y. Ren, M. Beinborn, and A.S. Kopin Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function J. Pharmacol. Exp. Ther. 321 2007 298 307
3. S. Al-Sabah, and D. Donnelly A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors Br. J. Pharmacol. 140 2003 339 346
4. S. Al-Sabah, F. Alasfar, G. Al-Khaledi, R. Dinesh, M. Al-Saleh, and H. Abul Incretin response to a standard test meal in a rat model of sleeve gastrectomy with diet-induced obesity Obes. Surg. 24 2014 95 101
5. B.K. Atwood, J. Lopez, J. Wager-Miller, K. Mackie, and A. Straiker Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis BMC Genomics 12 2011 14
6. J.E. Campbell, and D.J. Drucker Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab. 17 2013 819 837
7. E. Faivre, V.A. Gault, B. Thorens, and C. Holscher Glucose-dependent insulinotropic polypeptide receptor knockout mice are impaired in learning, synaptic plasticity, and neurogenesis J. Neurophysiol. 105 2011 1574 1580
8. E. Faivre, and C. Holscher Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model Alzheimers Res. Ther. 5 2013 20
9. B. Finan, T. Ma, N. Ottaway, T.D. Muller, K.M. Habegger, K.M. Heppner, H. Kirchner, J. Holland, J. Hembree, C. Raver, S.H. Lockie, D.L. Smiley, V. Gelfanov, B. Yang, S. Hofmann, D. Bruemmer, D.J. Drucker, P.T. Pfluger, D. Perez-Tilve, J. Gidda, L. Vignati, L. Zhang, J.B. Hauptman, M. Lau, M. Brecheisen, S. Uhles, W. Riboulet, E. Hainaut, E. Sebokova, K. Conde-Knape, A. Konkar, R.D. DiMarchi, and M.H. Tschop Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans Sci Transl Med 5 2013 209ra151
10. V.A. Gault, F.P. O'Harte, P. Harriott, and P.R. Flatt Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide Biochem. Biophys. Res. Commun. 290 2002 1420 1426
11. V.A. Gault, P.L. McClean, R.S. Cassidy, N. Irwin, and P.R. Flatt Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets Diabetologia 50 2007 1752 1762
12. R. Göke, H.C. Fehmann, T. Linn, H. Schmidt, M. Krause, J. Eng, and B. Goke Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells J. Biol. Chem. 268 1993 19650 19655
13. S.A. Hinke, R. Gelling, S. Manhart, F. Lynn, R.A. Pederson, K. Kuhn-Wache, F. Rosche, H.U. Demuth, D. Coy, and C.H. McIntosh Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP) Biol. Chem. 384 2003 403 407
14. J.J. Holst, F.K. Knop, T. Vilsboll, T. Krarup, and S. Madsbad Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes Diabetes Care 34 Suppl. 2 2011 S251 S257
15. V. Ionut, M. Burch, A. Youdim, and R.N. Bergman Gastrointestinal hormones and bariatric surgery-induced weight loss Obesity 21 2013 1093 1103
16. N. Irwin, P.L. McClean, F.P. O'Harte, V.A. Gault, P. Harriott, and P.R. Flatt Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice Diabetologia 50 2007 1532 1540
17. R. Jorgensen, V. Kubale, M. Vrecl, T.W. Schwartz, and C.E. Elling Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s) J. Pharmacol. Exp. Ther. 322 2007 148 154
18. T.J. Kieffer, C.H. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
19. W. Kim, and J.M. Egan The role of incretins in glucose homeostasis and diabetes treatment Pharmacol. Rev. 60 2008 470 512
20. S.J. Kim, C. Nian, S. Karunakaran, S.M. Clee, C.M. Isales, and C.H. McIntosh GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis PLoS One 7 2012 e40156
21. J. Korner, M. Bessler, W. Inabnet, C. Taveras, and J.J. Holst Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding Surg. Obes. Relat. Dis. 3 2007 597 601
22. B. Laferrere, S. Heshka, K. Wang, Y. Khan, J. McGinty, J. Teixeira, A.B. Hart, and B. Olivan Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes Diabetes Care 30 2007 1709 1716
23. P.L. McClean, N. Irwin, R.S. Cassidy, J.J. Holst, V.A. Gault, and P.R. Flatt GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet Am. J. Physiol. Endocrinol. Metab. 293 2007 E1746 E1755
24. A. Mieczkowska, N. Irwin, P.R. Flatt, D. Chappard, and G. Mabilleau Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality Bone 56 2013 337 342
25. K. Miyawaki, Y. Yamada, N. Ban, Y. Ihara, K. Tsukiyama, H. Zhou, S. Fujimoto, A. Oku, K. Tsuda, S. Toyokuni, H. Hiai, W. Mizunoya, T. Fushiki, J.J. Holst, M. Makino, A. Tashita, Y. Kobara, Y. Tsubamoto, T. Jinnouchi, T. Jomori, and Y. Seino Inhibition of gastric inhibitory polypeptide signaling prevents obesity Nat. Med. 8 2002 738 742
26. M.A. Nauck, M.M. Heimesaat, C. Orskov, J.J. Holst, R. Ebert, and W. Creutzfeldt Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J. Clin. Investig. 91 1993 301 307
27. A. Pocai Action and therapeutic potential of oxyntomodulin Mol. Metab. 3 2014 241 251
28. B. Thorens, A. Porret, L. Buhler, S.P. Deng, P. Morel, and C. Widmann Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor Diabetes 42 1993 1678 1682
29. R.C. Troke, T.M. Tan, and S.R. Bloom The future role of gut hormones in the treatment of obesity Ther. Adv. Chronic Dis. 5 2014 4 14
30. M.B. Wheeler, R.W. Gelling, C.H. McIntosh, J. Georgiou, J.C. Brown, and R.A. Pederson Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties Endocrinology 136 1995 4629 4639